Last updated: September 9, 2026
TEPMETKO is the brand name for tepotinib hydrochloride hydrate, an oral MET inhibitor approved for adults with metastatic non-small cell lung cancer whose tumors have MET exon 14 skipping alterations. The marketed product is a 225 mg immediate-release film-coated tablet taken as two tablets once daily with food, for a total dose of 450 mg daily [1]. Its excipient system is conventional, which creates opportunities in generic development, supply-chain competition, patient-centric reformulation, and manufacturing cost reduction rather than in a differentiated delivery platform.
What is the TEPMETKO formulation?
TEPMETKO uses a conventional immediate-release tablet formulation. The approved dosage form is a film-coated tablet containing 225 mg of tepotinib hydrochloride hydrate, equivalent to 225 mg of tepotinib [1].
| Attribute |
TEPMETKO specification |
| Active ingredient |
Tepotinib hydrochloride hydrate |
| Strength |
225 mg per tablet |
| Administration |
Oral |
| Recommended dose |
450 mg once daily |
| Daily tablet burden |
Two tablets |
| Release profile |
Immediate release |
| Administration condition |
With food |
| Dosage form |
Film-coated tablet |
| Therapeutic area |
MET exon 14 skipping-positive metastatic NSCLC |
| U.S. sponsor |
EMD Serono, Inc. |
| Originator |
Merck KGaA and regional affiliates |
The product’s food requirement is commercially relevant. The U.S. label instructs patients to take TEPMETKO with food, which may improve exposure and supports the product’s formulation performance [1]. A generic or lifecycle formulation that reduces food-effect sensitivity could offer a meaningful clinical and commercial distinction, subject to FDA approval.
What excipients are used in TEPMETKO tablets?
The U.S. prescribing information identifies the following inactive ingredients:
| Formulation component |
Excipient |
Likely technical function |
| Tablet core |
Mannitol |
Diluent and mouthfeel modifier |
| Tablet core |
Microcrystalline cellulose |
Diluent and compression aid |
| Tablet core |
Crospovidone |
Superdisintegrant |
| Tablet core |
Magnesium stearate |
Lubricant |
| Film coating |
Hypromellose |
Film-forming polymer |
| Film coating |
Titanium dioxide |
Opacifier and colorant |
| Film coating |
Talc |
Anti-tacking and coating aid |
| Film coating |
Ferric oxide yellow |
Colorant |
These excipients are widely used in oral solid dosage forms and are generally supported by established pharmaceutical use. The formulation does not depend on a novel lipid system, controlled-release polymer, osmotic technology, or specialized capsule shell.
The commercial importance of the excipients is therefore linked to manufacturability, tablet robustness, disintegration, coating uniformity, color matching, and supply reliability. Excipient selection alone is unlikely to create strong product differentiation unless it is connected to a measurable improvement in food effect, tablet burden, tolerability, or stability.
Why does TEPMETKO require administration with food?
Food administration is part of the approved dosing instructions. The label directs patients to take two tablets once daily with food [1].
For a generic developer, this creates three technical priorities:
- Matching the reference product’s fed-state exposure.
- Demonstrating acceptable dissolution across relevant pH conditions.
- Controlling tablet disintegration and drug-release behavior after meals.
Tepotinib is a highly active targeted oncology drug administered at a relatively high daily dose of 450 mg. The formulation must accommodate the active pharmaceutical ingredient while maintaining tablet hardness, coating integrity, and rapid release. Mannitol and microcrystalline cellulose provide a standard route to tablet bulk and compression performance. Crospovidone supports rapid breakup of the tablet after ingestion.
A formulation that changes particle size, polymorph, granulation method, lubricant level, or disintegrant concentration could alter exposure. Such changes may require comparative dissolution, pharmacokinetic, or bridging work depending on the regulatory pathway.
What formulation patents may protect TEPMETKO?
The main intellectual-property risks for TEPMETKO are likely to involve the active compound, crystalline or salt forms, therapeutic use, and manufacturing processes rather than the listed excipients themselves.
| Potential protection category |
Relevance to TEPMETKO |
| Composition-of-matter patents |
May protect tepotinib or related kinase-inhibitor structures |
| Salt and hydrate patents |
Relevant because the marketed active is tepotinib hydrochloride hydrate |
| Solid-form patents |
May cover polymorphs, hydrates, crystallinity, or particle properties |
| Method-of-use patents |
May cover MET exon 14 skipping-positive NSCLC or dosing regimens |
| Process patents |
May cover synthesis, purification, crystallization, or intermediate compounds |
| Formulation patents |
Could cover tablet composition, dissolution, stability, or food-effect control |
The excipient list in the U.S. label does not establish whether any particular excipient combination is patented. Generic applicants must separately review the FDA Orange Book, issued patents, patent-family status, terminal disclaimers, regulatory exclusivity, and litigation records before selecting a launch strategy.
The highest formulation-specific risk would arise from claims directed to the combination of tepotinib hydrochloride hydrate with a defined disintegrant, diluent, lubricant, coating system, particle-size distribution, or dissolution profile. A generic formulation using the same excipients could still avoid infringement if it uses materially different quantities, process conditions, solid-state properties, or claim limitations. That conclusion requires claim-by-claim analysis.
What commercial opportunities exist for TEPMETKO excipients?
Generic tablet manufacturing
The conventional excipient system supports multiple manufacturing routes, including direct compression, dry granulation, and wet granulation. The most attractive route depends on the powder-flow and compressibility characteristics of the selected tepotinib form.
Potential cost levers include:
- Using regional suppliers for mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate.
- Reducing coating weight while maintaining appearance and protection.
- Optimizing lubricant concentration to improve ejection without slowing dissolution.
- Selecting high-functionality excipients that reduce processing steps.
- Using continuous manufacturing for improved blend uniformity and throughput.
- Qualifying dual suppliers for critical excipients and pigments.
The commercial value of these changes is greatest in high-volume markets where generic pricing pressure makes manufacturing cost and supply continuity more important than minor differences in ingredient cost.
Excipient supply contracts
TEPMETKO’s excipients are commodity or established specialty pharmaceutical materials. Suppliers can compete through:
- Narrow particle-size specifications.
- Low-moisture grades.
- Improved flow and compressibility.
- Documented elemental-impurity control.
- Consistent microbiological quality.
- Global regulatory documentation.
- Dual-region manufacturing capacity.
Mannitol and microcrystalline cellulose may have greater formulation impact than the colorants because they influence tablet size, compressibility, disintegration, and manufacturing speed. Magnesium stearate is inexpensive but can have an outsized effect on dissolution if overmixed or used at excessive levels.
Patient-centric reformulation
The approved dose requires two 225 mg tablets daily. A 450 mg tablet could reduce tablet burden, but the larger tablet would create practical challenges involving swallowability, mechanical strength, dose uniformity, and exposure equivalence.
Other potential lifecycle concepts include:
- A smaller tablet with higher drug loading.
- A dispersible or orally disintegrating formulation.
- A formulation with reduced food dependence.
- A tablet optimized for patients with dysphagia.
- A blister pack that separates the daily dose.
- A calendarized pack that improves adherence.
These products would face a higher regulatory and development burden than a conventional generic. Their commercial value would depend on evidence that the new presentation improves adherence, administration, or exposure.
How strong is the TEPMETKO formulation strategy?
TEPMETKO’s excipient strategy is technically conservative and commercially reproducible. That is favorable for scale-up and generic development but limits formulation-based differentiation.
| Factor |
Assessment |
| Excipient availability |
Strong; ingredients are broadly available |
| Manufacturing complexity |
Moderate to low |
| Supply-chain concentration |
Generally manageable, subject to regional qualification |
| Tablet differentiation |
Limited |
| Food-effect opportunity |
Potentially meaningful |
| Patient-centric opportunity |
Moderate |
| Formulation patent risk |
Requires claim-specific review |
| Generic development feasibility |
Technically plausible, subject to bioequivalence and patent barriers |
| Biosimilar risk |
Not applicable; TEPMETKO is a small-molecule drug |
| Regulatory complexity |
Higher than a routine tablet because of oncology exposure and food-effect considerations |
The formulation is easier to reproduce than a modified-release or biologic product, but that does not eliminate legal or regulatory barriers. Tepotinib’s solid form, salt, hydrate state, particle characteristics, and method of manufacture can affect both equivalence and patent exposure.
What is the FDA regulatory status of TEPMETKO?
The FDA approved TEPMETKO in February 2021 under the accelerated approval pathway for adults with metastatic NSCLC whose tumors have MET exon 14 skipping alterations [2]. The approval was based on overall response rate and duration of response in the VISION study. The indication is biomarker-defined, requiring validated diagnostic testing.
The product is also authorized in other jurisdictions, including Japan and the European Union, under regional regulatory frameworks [3, 4]. Regional labels may differ in excipient disclosure, dosing language, indication wording, and post-approval commitments.
The regulatory status creates several commercial implications:
- Demand is tied to the size of the MET exon 14 skipping-positive population.
- Companion or complementary diagnostic access affects treatment volume.
- Generic entry depends on both regulatory approval and patent clearance.
- A formulation change may require additional clinical or pharmacokinetic evidence.
- Substitution rules may differ across the United States, Europe, and Japan.
What generic entry risks exist for TEPMETKO?
A conventional tablet generic would face four principal risks.
Bioequivalence and food-effect risk
The generic must reproduce clinically relevant exposure under the required dosing conditions. A formulation that performs differently in the fed state may fail comparative pharmacokinetic testing even if dissolution appears similar in vitro.
Solid-state risk
Tepotinib hydrochloride hydrate may have specific crystalline or hydration characteristics. Changes in solid form can affect solubility, stability, tablet performance, and exposure.
Method-of-use patent risk
A generic applicant may need to address patents covering treatment of MET exon 14 skipping-positive NSCLC, dosing, patient selection, or combination treatment. A label carve-out may be possible only if the protected use can be omitted without undermining the approved generic label.
Manufacturing-process risk
A process patent may cover crystallization, purification, or preparation of the active ingredient. A generic developer can reduce risk by using an independently designed process and documenting non-infringement.
Paragraph IV exposure, litigation timing, and launch eligibility depend on the current Orange Book listing, patent term, exclusivity status, and settlement terms. Those items should not be inferred from the excipient disclosure.
How does TEPMETKO compare with biologic oncology products?
TEPMETKO has no biosimilar pathway because tepotinib is a small molecule. Its competitive risks come from small-molecule generics, other MET inhibitors, alternative targeted therapies, and diagnostic-driven treatment selection.
Compared with biologic oncology products, TEPMETKO has:
- Lower formulation complexity.
- Lower manufacturing infrastructure requirements.
- No biosimilar comparability program.
- Greater exposure to conventional generic substitution.
- More flexibility for tablet reformulation.
- Greater sensitivity to solid-state and food-effect equivalence.
The main competitive products are other targeted therapies used in biomarker-selected NSCLC. Product differentiation depends on efficacy, tolerability, dosing convenience, brain-penetration data, diagnostic reach, and payer positioning rather than on excipients alone.
What licensing opportunities exist for TEPMETKO-related excipients?
Potential licensing or commercial arrangements include:
- Regional supply agreements for pharmaceutical-grade mannitol or microcrystalline cellulose.
- Co-development of a lower-food-effect formulation.
- Contract manufacturing of high-containment oncology tablets.
- Technology licensing for continuous tableting or coating.
- Packaging partnerships for adherence-oriented daily-dose presentations.
- Formulation development agreements for generic or authorized-generic products.
An excipient supplier is unlikely to obtain meaningful product exclusivity merely by supplying a standard ingredient. Greater value would arise from a protected co-processed excipient, a validated manufacturing process, or a formulation that produces a documented pharmacokinetic or stability advantage.
Key Takeaways
- TEPMETKO is a 225 mg immediate-release film-coated tablet containing tepotinib hydrochloride hydrate.
- The approved dose is two tablets once daily with food.
- Listed excipients include mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, titanium dioxide, talc, and ferric oxide yellow.
- The formulation uses established excipient technology and is technically reproducible.
- The strongest commercial opportunities are generic manufacturing, supply-chain optimization, food-effect reduction, tablet-burden reduction, and patient-centric packaging.
- Tepotinib’s small-molecule status means biosimilar risk does not apply.
- Key legal risks may involve active-ingredient, solid-form, method-of-use, and manufacturing patents rather than the excipients themselves.
- A generic developer must separately evaluate Orange Book listings, regulatory exclusivity, patent claims, Paragraph IV exposure, and litigation timing.
FAQs
Can TEPMETKO be reformulated as a single 450 mg tablet?
Potentially, but the larger tablet would require evidence addressing swallowability, mechanical strength, content uniformity, dissolution, stability, and pharmacokinetic equivalence.
Are TEPMETKO’s excipients suitable for direct compression?
The listed combination is compatible with conventional tablet manufacturing, but direct compression depends on the physical properties of the selected tepotinib hydrochloride hydrate and excipient grades.
Is a generic TEPMETKO formulation required to use the same excipients?
No. A generic applicant generally may use different inactive ingredients if the formulation meets applicable safety, quality, bioequivalence, labeling, and regulatory requirements.
Could removing mannitol create a commercially differentiated product?
Yes, if the alternative formulation improves tablet size, moisture control, cost, or robustness. The change would still require comparative quality and regulatory support.
Does TEPMETKO have biosimilar competition?
No. Tepotinib is a chemically synthesized small-molecule drug, so competition would arise through generic or other small-molecule pathways rather than biosimilar approval.
References
-
EMD Serono, Inc. (2024). TEPMETKO (tepotinib hydrochloride) tablets, for oral use: U.S. prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. FDA.
-
European Medicines Agency. (2022). Tepmetko: EPAR - Product information. EMA.
-
Merck KGaA. (2024). Annual report 2023. Merck KGaA.
